The European Patent Office (EPO) has published a patent application, EP2026029035A1, detailing a human antibody or antigen-binding fragment thereof designed to target a coronavirus mutant strain. The publication date is March 18, 2026. The application lists several International Patent Classification (IPC) codes, including C07K 16/10, A61K 39/395, and C12N 15/13, indicating its focus on antibody technology, pharmaceutical compositions, and genetic engineering related to biological molecules.

This publication represents the initial disclosure of the patent application and does not impose immediate compliance obligations on regulated entities. However, it is relevant for companies operating in the biotechnology and pharmaceutical sectors, particularly those involved in infectious disease research and development. The designation of inventors has not yet been filed, and the application is designated for several European countries, including Germany, France, and the United Kingdom.